Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer immunotherapy.

D L Lamm, D E Thor, V D Stogdill

    The Journal of Urology
    |November 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Bacillus Calmette-Guerin immunotherapy significantly reduced tumor recurrence in bladder cancer patients. A simple skin test predicted treatment response, aiding in personalized immunotherapy strategies for transitional cell carcinoma.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

    Urologic oncology·2011
    Same author

    Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis.

    Drug delivery·2009
    Same author

    Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?

    Cancer surveys·2004
    Same author

    Diet and nutrition in urologic cancer.

    The West Virginia medical journal·2003
    Same author

    Immunotherapy for bladder cancer.

    Current urology reports·2002
    Same author

    Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer.

    Cancer detection and prevention·2001
    Same journal

    On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

    The Journal of urology·2026
    Same journal

    Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

    The Journal of urology·2026
    Same journal

    Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

    The Journal of urology·2026
    Same journal

    The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

    The Journal of urology·2026
    Same journal

    Let's Shift the Focus from Death to Life after Fournier's Gangrene.

    The Journal of urology·2026
    Same journal

    Endourology and Nephrolithiasis.

    The Journal of urology·2026
    See all related articles

    Area of Science:

    • Urology
    • Immunotherapy
    • Oncology

    Background:

    • Transitional cell carcinoma (TCC) of the bladder is a significant health concern.
    • Intravesical and percutaneous Bacillus Calmette-Guerin (BCG) immunotherapy offers a treatment option for TCC.
    • Evaluating BCG's efficacy and predictive markers is crucial for optimizing patient outcomes.

    Observation:

    • A randomized controlled trial compared BCG immunotherapy with control in 57 TCC patients.
    • BCG treatment resulted in a self-limited cystitis and one case of hydronephrosis.
    • Patient follow-up ranged from 3 to 30 months.

    Findings:

    • BCG immunotherapy significantly reduced tumor recurrence rates compared to controls (21% vs. 50%, p=0.027).
    • The disease-free interval was significantly prolonged in patients receiving BCG (p=0.014).

    Related Experiment Videos

  • A positive conversion of the purified protein derivative (PPD) skin test indicated a favorable response to BCG, with significantly lower recurrence rates (6% vs. 38%, p=0.022).

    • Implications:

    • BCG immunotherapy is an effective treatment for transitional cell carcinoma of the bladder, reducing recurrence and prolonging disease-free survival.
    • The PPD skin test can serve as a valuable predictive marker for BCG immunotherapy response.
    • BCG offers a viable treatment option for patients with Stage B TCC and carcinoma in situ, including those unsuitable for cystectomy.